All Federal Contract IDV Awards
Help

Federal Supply Schedule 36F79719D0153

Award Date 5/15/19
Last Date to Order 4/30/26
Federal Agency
Veterans Integrated Service Network 12
Awardee
Genzyme Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
Federal Supply Schedule V797D60724
Logo for Veterans Integrated Service Network 12 (VA - VHA)
This Federal Supply Schedule contract, awarded to Genentech USA, Inc., a foreign-owned biotechnology company, provides the U.S. Department of Veterans Affairs (VA) and other federal agencies access to a wide range of pharmaceutical products and services. The $7.7 billion contract has a period of performance through September 2023 and was established under the GSA's Pharmaceuticals and Drugs schedule. Under this IDV, Genentech will supply critical medical products to support federal...
Federal Supply Schedule 36F79723D0219
Logo for Veterans Integrated Service Network 12 (VA - VHA)
This Federal Supply Schedule contract with the Department of Veterans Affairs is a $4.9 billion multiple-award vehicle awarded to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the provision of drugs, pharmaceuticals, and hematology-related products. The contract has an ultimate completion date of September 14, 2028. Under this Federal Supply Schedule, Genentech has been awarded several delivery orders by the Department of Health and Human Services' Office of...
Federal Supply Schedule 36F79720D0213
Logo for Veterans Integrated Service Network 12 (VA - VHA)
The U.S. Department of Veterans Affairs (VA) has awarded a $19.3 million Federal Supply Schedule (FSS) contract to Servier Pharmaceuticals LLC, a pharmaceutical company, to provide drugs, pharmaceuticals, and hematology-related products. The contract has a period of performance through March 14, 2026. Under this FSS contract, the VA has placed multiple delivery orders for Servier's specialty oncology medications, such as pegaspargase (Oncaspar) and asparlas, to support cancer treatment...
Federal Supply Schedule 36F79724D0019
Logo for Veterans Integrated Service Network 12 (VA - VHA)
This Federal Supply Schedule contract, awarded by the U.S. Department of Veterans Affairs to Genmab US Inc., is for the procurement of drugs, pharmaceuticals, and hematology-related products (FSC 65 I B). The contract has a ceiling value of $750,000.00 and a period of performance from November 15, 2023, to November 14, 2028. The contract was awarded on a multiple-award basis and does not utilize any set-asides. As a Federal Supply Schedule contract, it provides a streamlined procurement...
Blanket Purchase Agreement 36F79719D0153-36E79724A0018
Logo for National Acquisition Center (VA)
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026. The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
Federal Supply Schedule 36F79719D0247
Logo for Veterans Integrated Service Network 12 (VA - VHA)
The U.S. Department of Veterans Affairs (VA) has awarded multiple Firm Fixed Price delivery orders and Blanket Purchase Agreements (BPAs) to UCB, Inc., a global biopharmaceutical company, under the VA's General Services Administration (GSA) Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The delivery orders, valued between $65,982.84 and $370,099.80, are for the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. UCB, Inc. also holds two...
Federal Supply Schedule 36F79719D0108
Logo for Veterans Integrated Service Network 12 (VA - VHA)
Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., holds a $225,000 Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract with the General Services Administration (GSA). Under this multiple award IDIQ contract, Amicus Therapeutics US, LLC has been awarded various delivery orders by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to provide the pharmaceutical product Galafold (migalastat) to support healthcare services for...
Federal Supply Schedule 36F79719D0283
Logo for Veterans Integrated Service Network 12 (VA - VHA)
The Department of Veterans Affairs (VA) Veterans Health Administration awarded Lundbeck LLC a 5-year Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs with a potential value of $124 million. Through this contract vehicle, the VA and other federal agencies can procure Lundbeck's portfolio of medications used to treat neurological conditions prevalent among veterans, including Sabril (vigabatrin) for treatment-resistant seizures, Xenazine (tetrabenazine) for chorea...
Federal Supply Schedule 36F79722D0228
Logo for Veterans Integrated Service Network 12 (VA - VHA)
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
Federal Supply Schedule 36F79725D0050
Logo for Veterans Integrated Service Network 12 (VA - VHA)
This Federal Supply Schedule (FSS) contract was awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency within the U.S. federal government. The contract, valued at up to $225,000.00, was awarded to Geron Corp, a for-profit manufacturer of goods, for a period of performance from January 15, 2025 to January 14, 2030. The contract is for the provision of 65 I B, DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS. This indicates that the contracted products and...

Genzyme Corporation, doing business as Sanofi Genzyme, has been awarded a $659 million multiple-award Federal Supply Schedule (FSS-61-IB) contract by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to provide pharmaceuticals and drugs. This IDV allows the VHA to issue delivery orders for a broad range of drug products from Genzyme's portfolio over a 5-year period to support healthcare programs for veterans. Genzyme has also been awarded a $4 million single-award Blanket Purchase Agreement (BPA) from the VA National Acquisition Center specifically for the specialty drugs Eliglustat (Cerdelga) and Lemtrada.

The delivery orders issued under Genzyme's IDVs are primarily for oncology and rare disease medications such as Eliglustat, Lemtrada, and Caprelsa, with no set-aside designations used. Genzyme fulfills these firm fixed price orders, valued from thousands to hundreds of thousands of dollars, by delivering the pharmaceuticals to VA medical facilities across the country from its places of performance in locations like Cambridge, MA and Riverwoods, IL. These IDVs enable the VHA and other federal healthcare agencies efficient access to Genzyme's product portfolio to serve veterans, military members, and other patients.

Generated 7/18/25, 10:05 AM